原料药 API
具备 GMP / DMF 注册就绪度的原料药（API）与候选药物 · 每条标明用途、适应症与为何值得上线
Listing Logic · Why These Products
This category is not a mere directory listing—each product is selected against the four criteria below and comes with both its 'use' and 'why it is listed' so buyers can quickly assess fit. Products are drawn from Unibest's API & Candidates supply catalog and posted after dual qualification and demand screening.
We prioritize APIs already GMP/DMF-ready that can directly support regulatory filing, avoiding the compliance cost of building from scratch.
We target chronic long-term therapies, (WHO) public-health procurement and specialty must-have scenarios with low, predictable demand volatility.
We include first-in-class mechanisms, first approvals or molecules addressing resistance/unmet need, offering differentiated pricing power.
We also tag the number of linked intermediates—deeper in-house intermediate coverage means higher feasibility for scale-up and cost reduction.
Browse by Indication
Pick a class to see only APIs for that disease areaDiabetes, obesity, dyslipidemia, NASH and other metabolic diseases
Hypertension, heart failure, anticoagulation, chronic kidney disease
Solid tumours, haematologic malignancies, myeloproliferative diseases
Antiviral, antibacterial, antifungal, HIV / hepatitis
RA, psoriasis, atopic dermatitis, IBD
Epilepsy, pain, depression & anxiety, neurodegeneration
Acid-related, GI motility, diarrhoea, liver disease
COPD, asthma and other airway diseases
Menopausal symptoms, urological conditions
Glaucoma, ocular surface disease
Skin infection, dermatologic inflammation
Local anaesthesia, postoperative analgesia
Allergic rhinitis, urticaria
Companion-animal ectoparasiticides
Browse by Patent Expiry
The cliff decides when to act — filter by window firstCompound patent expired — generic sourcing and registration feasible
Cliff approaching — lock in API supply and filing schedule early
Mid-term opportunity — start process development and DMF work
Still on-patent — typically licensing or clinical supply
No expiry on file — request a patent assessment for this molecule
Expiry years are compiled from public sources and estimated on compound patents in major markets (US / EU). They exclude polymorph, process and formulation patents, term extensions and paediatric exclusivity. Values marked indicative are directional; values marked to-verify are inferred from filing era. Actual generic entry timing depends on national patent offices and the Orange Book.
Resmetirom
Non-alcoholic steatohepatitis (MASH/NASH) with hepatic fibrosis
The world's first approved MASH therapy, opening a vast untreated blue-ocean; numerous follow-on pipelines will scale API demand alongside the entire class.
- CAS
- 920509-32-6
- Therapeutic Area
- Metabolism / Hepatology
- Target / Mechanism
- THRB
- Labeled Purity
- 99%+
Fexuprazan
Gastroesophageal reflux disease (GERD) and erosive esophagitis
A next-generation potassium-competitive acid blocker (P-CAB) with faster onset and no food effect versus PPIs, the upgrade direction for acid-related disease.
- CAS
- 1902954-60-2
- Therapeutic Area
- Gastroenterology / Acid-related
- Target / Mechanism
- ATP4A·ATP4B
- Labeled Purity
- 99%+
Vonoprazan
Reflux esophagitis, gastric ulcer; eradication of Helicobacter pylori with antibiotics
The first marketed P-CAB with stronger, more durable acid suppression and markedly higher H. pylori eradication; especially sizable demand in high-H. pylori Asian markets.
- CAS
- 881681-00-1
- Therapeutic Area
- Gastroenterology / H. pylori
- Target / Mechanism
- ATP4A·ATP4B
- Labeled Purity
- 99%+
- Patent scope
- Japan compound patent; US later
Devazepide
Exploratory indications related to gastrointestinal motility and appetite regulation
A classic cholecystokinin-receptor antagonist research molecule, commonly used in basic studies of digestion physiology and appetite regulation.
- CAS
- 103420-77-5
- Therapeutic Area
- Gastroenterology / Metabolism
- Labeled Purity
- 99+%
- Patent scope
- 1990s compound patent; expired per 20-yr term estimate — to be verified
Dexecadotril
Symptomatic treatment of acute diarrhea
An anti-secretory antidiarrheal that does not inhibit intestinal motility and pairs with rehydration, widely used in pediatric acute diarrhea.
- CAS
- 112573-72-5
- Therapeutic Area
- Gastroenterology
- Labeled Purity
- 98%+
- Patent scope
- Cadotril-class older product; compound patent expired
Supply source: Unibest API & Candidates supply catalog, sourced and delivered by Unibest. Therapeutic area, indication and selection rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability is subject to DMF/GMP documentation and the technical agreement confirmed at order.